Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA

Detalles Bibliográficos
Autores principales: Wehler, Elizabeth, Boytsov, Natalie, Nicolay, Claudia, Herrera-Restrepo, Oscar, Kowal, Stacey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081650/
https://www.ncbi.nlm.nih.gov/pubmed/31712980
http://dx.doi.org/10.1007/s40273-019-00857-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081650/
https://www.ncbi.nlm.nih.gov/pubmed/31712980
http://dx.doi.org/10.1007/s40273-019-00857-7

Ejemplares similares